The Latest Breaking News from FDA

This robotic AI stock is a “buy and hold” stock for the long term despite its lofty valuation.

Eli Lilly's two major GLP-1 drugs have dominated headlines, but a slate of new treatments in development—and some already available—suggest a bright future.

Australia recently became the first country to legalize both MDMA and psilocybin-assisted psychiatric therapy

The FDA has recently authorized the sale of Zyn nicotine pouches, marking a pivotal moment in tobacco harm reduction. As concerns about traditional smoking persist, nicotine pouches present a viable alternative for adult smokers. This approval underscores their potential public health benefits, despite challenges surrounding youth appeal.